Lasmiditan + Alprazolam + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recreational Drug Use
Conditions
Recreational Drug Use, Prescription Drug Abuse (Not Dependent)
Trial Timeline
Sep 15, 2017 → Nov 20, 2017
NCT ID
NCT03286218About Lasmiditan + Alprazolam + Placebo
Lasmiditan + Alprazolam + Placebo is a phase 1 stage product being developed by Eli Lilly for Recreational Drug Use. The current trial status is completed. This product is registered under clinical trial identifier NCT03286218. Target conditions include Recreational Drug Use, Prescription Drug Abuse (Not Dependent).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03286218 | Phase 1 | Completed |
Competing Products
4 competing products in Recreational Drug Use
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lorazepam + AZD7325 + Placebo | AstraZeneca | Phase 1 | 33 |
| ACT-541468 + Suvorexant + Zolpidem + Placebo | Idorsia | Phase 1 | 28 |
| PF614 + Oxycodone | Ensysce Biosciences | Phase 1 | 25 |
| PF614 + Oxycodone Hydrochloride 40 mg + Placebo | Ensysce Biosciences | Phase 1 | 25 |